Annals of Oncology Advance Access published online on December 15, 2005
Annals of Oncology, doi:10.1093/annonc/mdj099
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 United States Food and Drug Administration, Center for Drug Evaluation and Research Office of New Drugs, Office of Oncology Drug Products, Division of Drug Oncology Products, Silver Spring, MD, USA
* To whom correspondence should be addressed. Purpose: This paper summarizes the role of external advisors in oncology drug development and regulation from a global perspective. Design: Recently, representatives from the United States Food and Drug Administration, European Medicines Agency, the Japanese Pharmaceuticals and Medical Devices Agency, the Australian Therapeutic Goods Administration and Health Canada held a meeting in conjunction with the American Society of Clinical Oncology meeting. The role of external advisors in oncology drug development and regulation in each of these jurisdictions was presented and discussed. Results: All regulatory bodies described have experience with two forms of outside expertise: advice from individual experts and advice from a group of experts assembled as an advisory group. Regulatory jurisdictions use individual experts variably. In some regions, individual experts provide advice based on knowledge and experience during the drug development phase or in the planning phase for the submission of a drug registration package. In other regions, these individuals serve as external evaluators with the primary responsibility for the review of a clinical trials package submitted for drug registration. Advisory boards have been formalized in all jurisdictions discussed. Advisory boards have a role in discussing specific applications as well as broad policy issues. A common theme is a composition of a core panel of experts with augmentation by additional expertise as needed for consideration of specific scientific questions. In all jurisdictions, advisory board recommendations are not binding on the regulatory body. Conclusions: Global oncology drug development and registration involves the use of experts by regulatory authorities. The types of experts needed, the expert's role and the transparency of the advisory process reflect the individual needs in different regions.
Received August 22, 2005
Revised November 4, 2005
Accepted November 7, 2005
review
The advisory process for anticancer drug regulation: a global perspective
A. T. Farrell 1 *,
I. Papadouli 2,
A. Hori 3,
M. Harczy 4,
B. Harrison 5,
W. Asakura 3,
M. Marty 6,
R. Dagher 1,
and
R. Pazdur 1
2 European Medicines Agency, London, UK
3 Pharmaceuticals and Medical Devices Agency, Tokyo, Japan
4 Division of Antineoplastic Drugs, Bureau of Metabolism, Oncology and Reproductive Sciences, Therapeutic Products Directorate, Ottawa, ON, Canada
5 Therapeutic Goods Administration, Symonston, Australia
6 Saint Louis Hospital, Paris, France
A. T. Farrell, E-mail: farrella{at}cder.fda.gov
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Kudrin Challenges in the Clinical Development Requirements for the Marketing Authorization of New Medicines in Southeast Asia J. Clin. Pharmacol., March 1, 2009; 49(3): 268 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Casali and On behalf of the Executive Committee of ESMO The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO) Ann. Onc., December 1, 2007; 18(12): 1923 - 1925. [Full Text] [PDF]
|
|
|
|
|
|
D. Kerr Now the New Year reviving old desires Ann. Onc., January 1, 2007; 18(1): 3 - 3. [Full Text] [PDF]
|
|